You are here: Industry Insights > Ironwood

News List

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS (linaclotide) 72 mcg Dosage Strength firstwordpharma
May 27, 2021
IRWD, announced today that, with its partner AbbVie Inc., providing a license to Teva's ANDA seeking approval to market a generic version of 72 mcg LINZESS® (linaclotide) prior to the expiration of the companies' applicable patents.
AstraZeneca amends collaboration with Ironwood for Linzess in China worldpharmanews
September 20, 2019
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong, S.A.R., China and China Macau, S.A.R., China for Linzess (linaclotide) ...
Allergan and Ironwood's IBS-C push links patients to telemedicine fiercepharma
May 09, 2019
The “Oh My Gut!” effort highlights the multiple symptoms of irritable bowel syndrome with constipation—and aims to ease the path to diagnosis.
With split-up nearing, Ironwood adds 35 more to already-hefty layoff tally fiercepharma
February 24, 2019
Last summer, Ironwood pink-slipped 40 staffers as it prepared to split itself into two companies. But it turns out those layoffs were only the beginning.
Ironwood and Allergan settle Linzess patent litigation with Mylan pharmaceutical-technology
January 07, 2019
Ironwood Pharmaceuticals and Allergan have entered an agreement with Mylan Pharmaceuticals to settle patent litigations over generic versions of Linzess (linaclotide) medicine.....
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation pharmafocusasia
January 04, 2019
Ironwood Pharmaceuticals, Inc. and Allergan plc announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. resolving patent litigations brought in.....
Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts pharmafile
August 09, 2018
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back to AstraZeneca, terminating an agreement between the two firms that was struck in 2016.
Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the process fiercepharma
August 08, 2018
Zurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound up on the scrap heap.
Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease americanpharmaceuticalreview
June 27, 2018
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).
Ironwood's 'No Angel' campaign taps into stigma around gout fiercepharma
May 08, 2018
Shrimp and sausage haloes circle above actors’ heads in Ironwood Pharmaceutical’s first campaign for gout treatment Duzallo. The unusual crowns serve as visual reminders that while many patients may not always be perfect food choice angels...

Previous page 1 2 Next page